Anjiotensin Konverting Enzim İnhibitörü ve Anjiotensin Reseptör Blokeri İlaç Tedavilerinde "Karın Ağrısı"
Yükleniyor...
Tarih
2016
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Anjiotensin konverting enzim inhibitörleri (ACEİ) ve anjiotensin reseptör blokerleri (ARB) hipertansiyon tedavisinde ilk sırada reçete edilen ilaçlar arasındadır. Bu grup ilaçların farkındalık düzeyi düşük bir yan etkisi de; intestinal ödeme bağlı olarak ortaya çıkan karın ağrısı ataklarıdır. Bu advers etki ile ilgili yayınlar olgu sunumu ve literatür taramaları şeklindedir. Gereç ve Yöntem: Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi etik kurulundan onay alınarak, aynı hastanenin iç hastalıkları polikliniklerine herhangi bir şikayetle müracaat etmiş 8736 hastadan hipertansiyon endikasyonu ile ACEİ ve ARB kullanmakta olduğu tespit edilen 1010 hasta çalışmaya dahil edildi. Hastaların bu ilaçları kullanmaya başladıktan sonra oluşan dil-dudakta şişlik, öksürük ve karın ağrısı semptomları sorgulandı. Karın ağrısı şikayeti olup herhangi bir patoloji saptanamayan hastalar, çalışmanın hedefini oluşturacak grup olarak belirlendi. Bulgular: Hastaların 650 (%64.3)'si kadın ve 360 (%35.6)'i erkek idi. Yaş ortalamaları 528.02 idi. 553 (%55.3) 'ü ARB ve 447 (%44.7)'si ACEİ kullanmaktaydı. Hastaların ilacı kullanma süreleri ortalama ACEİ için 607.4 ay ARB için 568ay idi. Karın ağrısı tarifleyen 12 hastanın 7'si ACEİ, 5'i ARB kullanmaktaydı. Sonuç: ACEİ ve/veya ARB kullanımında intestinal anjioödeme bağlı olarak gelişen karın ağrısı görülebilmektedir. Bu ilaçlarla gelişebilecek gastrointestinal manifestasyonların farkındalığı arttıkça bu klinik semptom hekimler tarafından daha iyi tanınacaktır.
Objective: Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are the first line drugs for the treatment of hypertension. Abdominal pain due to intestinal edema is another adverse effect which is not well recognized and so with lower levels of awareness. Data about this adverse effect is insufficient and limited with case reports. Materials and Methods: This study was approved by the Local Ethics Committee conducted at Meram Faculty of Medicine, Necmettin Erbakan University. A total of 8736 patients were evaluated who were admitted to outpatient clinic of internal medicine, Meram Faculty of Medicine. A total of 1010 patients were included in the study who were on ACEI or ARB therapy. The new symptoms of angioedema on lips and tongue, cough and abdominal pain were questioned after usage of these drugs. The patients with abdominal pain but without any pathology were selected as the study group. Results: 650 (64.3%) of the patients were female and 360 (35.6%) of them were male. The mean age was 52±8.02. 553 (55.3%) of patients were on ARB and 447 (44.7%) of them were on ACEI therapy. The mean duration of drug usage was 60±7.4 months for ACEI and 56±8 months for ARB. A total of 12 patients (ACEI7, ARB5) were found with abdominal pain. Conclusion: angioedema may be seen during ACEI and/or ARB usage. The gastrointestinal adverse effects of these drugs may be better recognized by physicians as the level of awareness as increased.
Objective: Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are the first line drugs for the treatment of hypertension. Abdominal pain due to intestinal edema is another adverse effect which is not well recognized and so with lower levels of awareness. Data about this adverse effect is insufficient and limited with case reports. Materials and Methods: This study was approved by the Local Ethics Committee conducted at Meram Faculty of Medicine, Necmettin Erbakan University. A total of 8736 patients were evaluated who were admitted to outpatient clinic of internal medicine, Meram Faculty of Medicine. A total of 1010 patients were included in the study who were on ACEI or ARB therapy. The new symptoms of angioedema on lips and tongue, cough and abdominal pain were questioned after usage of these drugs. The patients with abdominal pain but without any pathology were selected as the study group. Results: 650 (64.3%) of the patients were female and 360 (35.6%) of them were male. The mean age was 52±8.02. 553 (55.3%) of patients were on ARB and 447 (44.7%) of them were on ACEI therapy. The mean duration of drug usage was 60±7.4 months for ACEI and 56±8 months for ARB. A total of 12 patients (ACEI7, ARB5) were found with abdominal pain. Conclusion: angioedema may be seen during ACEI and/or ARB usage. The gastrointestinal adverse effects of these drugs may be better recognized by physicians as the level of awareness as increased.
Açıklama
Anahtar Kelimeler
Anjiotensin konverting enzim inhibitörü, Anjiotensin reseptör blokeri, Karın ağrısı, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, Abdominal pain
Kaynak
Van Tıp Dergisi
WoS Q Değeri
Scopus Q Değeri
Cilt
23
Sayı
4
Künye
Arslan, Ş., Uçar, R., Uçar, E., Savut, B., Sayın, S., Türkmen, K. (2016). Anjiotensin konverting enzim inhibitörü ve anjiotensin reseptör blokeri ilaç tedavilerinde "karın ağrısı". Van Tıp Dergisi, 23, 4, 313-317.
